期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

地西他滨联合半量CAG治疗复发难治性急性髓细胞白血病的疗效分析 被引量：1

Analysis of the Efficacy of Decitabine Combined with Half Quantity of CAG Regiment for the Treatment of Refractory or Relapsed Acute Myeloid Leukemia
下载PDF
导出
摘要 [目的]探讨地西他滨联合半量阿克拉霉素+阿糖胞苷+粒系集落刺激因子(CAG)方案治疗复发难治性急性髓细胞白血病(AML)的疗效.[方法]回顾性分析2012年2～10月在本院血液科接受地西他滨治疗的7例复发难治AML患者的临床资料,评价其疗效和不良反应.[结果]完全缓解患者3例,部分缓解患者2例,无效患者2例,总有效率为71.4％(5/7)；血液学不良反应发生率为100％,感染发生率为71.4％(5/7),轻度肝功能损伤率42.9％(3/7),无严重出血、恶心呕吐不良反应.[结论]地西他滨联合半量CAG可有效治疗复发难治性急性髓细胞白血病,虽然血液学不良反应较重,感染的发生率较高,但患者基本上可耐受,给予相应抗炎及支持治疗可得到有效控制.
作者 高然 于锦香 高峰 蔡大利 王柏勋 潘登 张蕊 颜晓菁 李艳
机构地区 中国医科大学附属第一医院血液科
出处 《医学临床研究》 CAS 2013年第6期1125-1126,1129,共3页 Journal of Clinical Research
关键词 白血病 髓样 急性/药物疗法 Leukemia Myeloid Acute/DT
分类号 R733.71 [医药卫生—肿瘤]
  • 相关文献

参考文献13

  • 1Schoofs T,Müller Tidow C. DNA methylation as a pathogenic event and as a therapeutic target in AML[J].Cancer Treatment Reviews,2011,(Suppl 1):S13-S18.
  • 2韩颖,罗建民,贾晓辉,王福旭,姚丽,杜行严.白血病患者造血细胞磷酸酶与半胱氨酸蛋白酶基因表达及其临床意义[J].中华内科杂志,2006,45(5):363-365. 被引量：18
  • 3方宝枝,何广胜,吴德沛,孙爱宁,金正明,仇惠英,傅铮铮,唐晓文,苗瞄,韩悦,赵晔,王荧,王秀丽,吴小津.地西他滨治疗成人急性髓细胞白血病的临床观察[J].肿瘤,2011,31(11):1022-1025. 被引量：32
  • 4Steensma DP,Baer MR,Slack JL. Multi-center study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes:the alternative dosing for outpatient treatment (ADOPT) trial[J].Journal of Clinical Oncology,2009,(23):3842-3848.doi:10.1200/JCO.2008.19.6550.
  • 5Harris NL,Jaffe ES,Diebold J. The World Health Or ganization classification of neoplastic diseases of the hematopoietic and lymphoid tissue:Report of the clinical advisory committee meeting-Airlie house,Virginia,November 1997[J].Journal of Clinical Oncology,1999,(12):1419-1432.
  • 6钱芳,张刚.DNA甲基化与肿瘤的相关研究进展[J].医学综述,2013,19(3):445-448. 被引量：14
  • 7董玉玮,侯进慧,朱必才,李培青,庞永红.表观遗传学的相关概念和研究进展[J].生物学杂志,2005,22(1):1-3. 被引量：65
  • 8Jin B,Ernst J,Tiedemann RL. Linking DNA methyltransferases to epigenetic marks and nucleosome structure genome-wide in human tumor cells[J].Cell Research,2012,(05):14111424.
  • 9Lubbert M,Ruter BH,Claus R. A multicenter phase Ⅱtrial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy[J].Hematological Oncology,2012,(03):393-401.
  • 10Kantarjian HM,Thomas XG,Dmoszynska A. Multicenter,randomized,open-label,phase Ⅲ trial of decitabine versus patient choice,with physician advice,of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia[J].Journal of Clinical Oncology,2012,(21):2670-2677.

二级参考文献61

  • 1罗建民,刘泽林,郝洪岭,董作仁,王福旭,大野竜三.急性白血病细胞HCP基因的突变分析[J].临床血液学杂志,2004,17(5):271-273. 被引量：6
  • 2CHESON B D,BENNETT J M,KOPECKY K J,et al.Revised recommendations of the International Working Group for Diagnosis,Standardization of Response Criteria,Treatment Outcomes,and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia[J].J Clin Oncol,2003,21(24):4642-4649.
  • 3STRESEMANN C,BRUECKNER B,MUSCH T,et al.Functional diversity of DNA methyltransferase inhibitors in human cancer cell lins[J].Cancer Res,2006,66 (5):2794-2800.
  • 4WlDSCHWENDTER A,M(U)LLER H M,FIEGL H,et al.DNA methylation in serum and tumors of cervical cancer patients[J].Clin Cancer Res,2004,10 (2):565-571.
  • 5MURAl M,TOYOTA M,SATOH A,et al.Aberrant DNA methylation associated with silencing BNIP3 gene expression in haematopoietic tumours[J].Br J Cancer,2005,92 (6):1165-1172.
  • 6HASEGAWA D,MANABE A,KUBOTA T,et al.Methylation status of the p15 and p16 genes in paediatric myelodysplastic syndrome and juvenile myelomonocytic leukaemia[J].Br J Haematol,2005,128 (6):805-81 2.
  • 7JIANG Y,DUNBAR A,GONDEK L P,et al.Aberrant DNA methylation is a dominant mechanism in MDS progression to AML[J].Blood,2009,113 (6):1315-1325.
  • 8Sl J,BOUMBER Y A,SHU J,et al.Chromatin remodeling is required for gene reactivation after decitabine-mediated DNA hypomethylation[J].Cancer Res,2010,70 (17):6968-6977.
  • 9ISSA J P,GARCIA-MANERO G,GILES F J,et al.Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza2'-deoxycytidine (decitabine) in hematopoietic malignancies[J].Blood,2004,103 (5):1635-1640.
  • 10BLUM W,KLISOVIC R B,HACKANSON B,et al.Phase Ⅰ study of decitabine alone or in combination with valproic acid in acute myeloid leukemia[J].J Clin Oncol,2007,25 (25):3884-3891.

共引文献115

同被引文献7

医学临床研究
2013年 第6期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部